You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm attributed its quarterly and annual revenue gains primarily to sales of COVID-19 testing sample collection devices.
Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.
Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
The firm said it is currently also developing Novodiag Resp-4, a molecular test for the rapid, on-demand detection of the viruses.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.
For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019.
The firm said its test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost, and labor.
The drugstore will sell Pixel by Labcorp kits in up to 6,000 stores, with the goal of providing a testing option at stores that don't currently have on-site testing.
The firm guided for 2021 revenue growth of between 5 percent and 8 percent, citing "a persistently uncertain business environment."
The MiQLab system can look for 27 different targets, allowing the detection of SARS-CoV-2 as well as the determination of specific variants.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.
The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
TruGenX claims that Thermo Fisher's technical support did not resolve testing issues for months, damaging its business and reputation.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
The firm's rapid immunoassay revenues jumped ninefold due to more than $587 million in sales of SARS-CoV-2 viral antigen tests.
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.